Michal Klimek

Dr. Michal Klimek

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RDRuth Josephine Donner
Ruth Josephine Donner
MKMichal Klimek
Michal Klimek
GSGerald Schmidinger
Gerald Schmidinger
Purpose: This study aimed to refine the criteria for EndoART implantation regarding posterior corneal irregularity; to improve the selection of candidates for this synthetic alternative to endothelial keratoplasty. Methods: This study analyzed the impact of posterior corneal surface elevation differences; anterior chamber depth (ACD); and preoperative corneal pachymetry on the success of EndoART implant adhesion. Patients undergoing EndoART implantation at the Medical University of Vienna were assessed using OCT to measure corneal irregularities. Postoperative outcomes, including re-bubbling rates; implant adhesion; and visual acuity changes, were monitored. Results: EndoART successfully adhered in eyes with moderate posterior irregularities (elevation differences up to 204 µm). Severe irregularities (elevation differences > 200 µm) resulted in implant detachment. No significant correlation was found between corneal pachymetry or ACD and adhesion failure. Glaucoma devices and prior penetrating keratoplasty did not significantly affect adhesion. Some cases required re-bubbling, and patients reported pain reduction and moderate improvements in visual acuity. Conclusions: This study found that EndoART implantation can be successful despite posterior corneal irregularity. EndoART represents a viable solution for patients with poor biological graft survival prognosis, including those with glaucoma or prior surgeries, expanding its potential use and addressing the global donor cornea shortage.

1 February 2025 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
JAJulia Aschauer
Julia Aschauer
MKMichal Klimek
Michal Klimek
RDRuth Donner
Ruth Donner
ISIrene Steiner
Irene Steiner
JLJan Lammer
Jan Lammer
GSGerald Schmidinger
Gerald Schmidinger
Purpose: Corneal allograft survival is dramatically decreased in high-risk (HR) host beds. The purpose of this study was to investigate the outcome of HR keratoplasty (KP) in a single-center tertiary referral clinic and to determine risk factors for graft failure. Methods: This retrospective study included adults referred for HR penetrating KP between 2014 and 2022. HR criteria were history of re-KP, stromal neovascularization in ≥ 2 quadrants, and signs of significant inflammation/manifest perforation at the time of surgery. The primary endpoint was graft failure within the first postoperative year. Donor endothelial cell count, donor age, stromal neovascularization, and manifest perforation/acute inflammation at surgery were independent variables in the univariate/multivariable logistic regression. Results: Graft survival 1 year after surgery was 56.2% (CI: 45.7, 66.4), 68.3% (CI: 59.3, 76.4), and 70.2% (CI: 56.6, 81.6) after the first, second, and third KP, respectively. The presence of perforation/acute inflammation at baseline was found to be an independent factor statistically significantly associated with graft failure. Graft failure occurred in 190 (51%) of 375 KPs in 257 patients during overall observation. The median time (95% CI) from KP until graft failure was 559 (392, 994) days for the 1st KP, 1052 (833, 1375) days for the 2nd KP and 1089 (689, inf) for the 3rd KP. The most frequent cause was immune rejection (n=55, 29%), whereas in a majority (n=66, 35%) the reason remained undefined. The median time (95% CI) until neovascularization (re-) formation after KP was 739 days (550, inf) and 1566 (1055, inf) days for the 1st and the 2nd KP. Conclusion: Acute inflammation/perforation at the time of surgery were the major risk factors for graft failure in HR KP. Reduced survival rates for HR KPs were confirmed in this study, which highlights the need for further developments in the treatment of these patients.

Verified
Journal Article
Open access
PDF file
RDRuth Josephine Donner
Ruth Josephine Donner
GSGerald Schmidinger
Gerald Schmidinger
MKMichal Klimek
Michal Klimek
JAJulia Aschauer
Julia Aschauer
Background/Aims: To investigate the effectiveness of an accelerated high-fluence peripheral crosslinking (pCXL) treatment protocol for corneal neovascularization (cNV) and the viability of optical coherence tomography angiography (OCTA) to monitor cNV dynamics. Methods: This pilot study included six eyes of six adult patients with cNV in at least one corneal quadrant who were treated with pCXL (7.2 J/cm2, 9 mW). The degree of cNV regression was monitored with slit lamp photography and anterior segment OCTA. The main outcome measure was total vessel area one and four weeks after treatment. Results: OCTA allowed for the objective monitoring of vascular metrics: The total vessel area declined from an average of 1025.4 mm2 (min: 0.13 mm2; max: 3637 mm2) at the baseline evaluation to 382.4 mm2 (min: 0.08 mm2; max: 1528 mm2) (p = 0.096). The total vessel length lessened from an average of 107.1 mm (min: 2.8 mm; max: 321.1 mm) to 47 mm (min: 2.6 mm; max: 156.5 mm) (p= 0.27). The average number of junctions at baseline decreased from 46.67 (min: 3; max: 166) to 26.5 (min: 0; max: 50) (p = 0.23). The junction density decreased from an average of 10.75/mm2 (min: 0.0002 /mm2; max: 36.5056/mm2) to 7.37/mm2 (avg.) (min: 0; max 18.7356/mm2) (p = 0.24). PCXL was performed safely without adverse effects, but vascular occlusion was not complete in all eyes. Conclusions: High-fluence pCXL may represent a valuable treatment option to achieve cNV regression, whilst the optimal fluence dose still remains to be defined. Anterior segment OCTA is an innovative tool for non-invasive, objective, and quantitative cNV monitoring.

1 September 2026 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
MKMichal Klimek
Michal Klimek
AFAndreas Földesi
Andreas Földesi
DBDejan Botic
Dejan Botic
VGValerie Golsch
Valerie Golsch
RKRafah Khandour
Rafah Khandour
PVPia Veronika Vécsei-Marlovits
Pia Veronika Vécsei-Marlovits
Purpose: To quantify the frequency, magnitude, and direction of inter-formula planning variability in intraocular lens (IOL) power calculation at the extremes of axial length, comparing seven European Society of Cataract and Refractive Surgeons (ESCRS)-hosted formulas and the Ladas Super Formula 2.0, and to identify preoperative predictors of clinically relevant disagreement. Methods: In this retrospective, single-center, paired within-eye planning study, the recommended IOL power and predicted spherical equivalent were generated for short (axial length 22 mm) and long (> 26 mm) eyes from identical biometry (IOLMaster 700) across the seven formulas on three IOL platforms. A clinically relevant discrepancy (ClinRel) was defined as a within-eye range ≥ 1 step (≥ 0.5 D) in recommended power or ≥ 0.25 D in predicted spherical equivalent across the seven formulas. Firth-penalized logistic regression identified predictors in the long stratum. Results: A total of 1020 eyes (551 short, 469 long) of 665 patients were analyzed. On the primary platform, ClinRel occurred in 98.2% of short and 62.7% of long eyes, reproduced on all three platforms and in one-eye-per-patient analyses. Per-formula mean signed differences vs Barrett Universal II were small (− 0.11 to +0.16 D), yet the seven formulas diverged by ≥ 2 steps in 33.8% of short eyes. Hill-RBF 3.0 was out-of-bounds in ~30% of eyes; the Ladas Super Formula 2.0 (n = 311) was not a directional outlier. In long eyes, axial length was the strongest predictor (Firth odds ratio 1.55 per 1 SD; 95% CI 1.23– 1.95), with no clean threshold (Youden axial length/corneal radius ratio 3.52; sensitivity 35.5%, specificity 96.0%). Conclusions: Modern IOL power formulas frequently disagree on the recommended power in short and long eyes despite comparable published accuracy. Because postoperative outcomes were not assessed, these findings quantify planning-level variability only; disagreement should alert surgeons to planning uncertainty in these eyes.

18 June 2025 in Expert Review of Ophthalmology
Verified
Journal Article
Closed access
MKMichal Klimek
Michal Klimek
ISIrene Steiner
Irene Steiner
GSGerald Schmidinger
Gerald Schmidinger
JLJan Lammer
Jan Lammer
JAJulia Aschauer
Julia Aschauer

1 June 2026 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
MKMichal Klimek
Michal Klimek
MTMaximilian Tamberger
Maximilian Tamberger
SSStephanie Schauer
Stephanie Schauer
DBDejan Botic
Dejan Botic
KMKata Mihaltz
Kata Mihaltz
PVPia Veronika Vécsei-Marlovits
Pia Veronika Vécsei-Marlovits
Purpose: To determine the frequency, magnitude, and direction of toric intraocular lens (IOL) planning discrepancies between the Johnson & Johnson (J&J) official calculator and European Society of Cataract and Refractive Surgeons (ESCRS)-hosted toric engines, and to identify preoperative predictors of clinically relevant disagreements. Methods: This retrospective, single-center study included 182 eyes of 127 patients undergoing toric IOL implantation (TECNIS). For each eye, planning results were generated using identical biometric data (IOLMaster 700, CASIA2 keratometry) across all calculators. The primary comparison was J&J with posterior corneal astigmatism correction enabled (PCA-ON) versus ESCRS-Barrett – secondary comparisons included Kane, EVO 2.0, and Hoffer QST. Clinically relevant discrepancy (ClinRel) was defined as a toric cylinder step difference ≥ 1 and/or axis difference ≥ 10°. Logistic regression, including Firth-penalized estimation, identified predictors of ClinRel. The primary analysis set comprised one eye per patient (n=127). Results: ClinRel between J&J PCA-ON and Barrett occurred in 59.8% of eyes (76/127; 95% CI: 51.1– 68.0%), driven almost only by step differences. J&J PCA-ON recommended a higher step in 56.7% of eyes, with only 2.4% showing the opposite. Discrepancies were concentrated in with-the-rule eyes (72.3%) and nearly absent in against-the-rule eyes (5.6%). Rates were higher for secondary engines (Kane 83.8%, EVO 74.4%, Hoffer QST 76.7%). An Alpins-style paired-planning analysis yielded a Correction Index of 1.20, with the Difference Vector concentrated at the vertical meridian (84°). Posterior corneal astigmatism grade was the strongest independent predictor (Firth-adjusted OR = 203.5; p=0.014). An empirical PCA threshold of 0.36 D (Youden index; sensitivity 91.6%, specificity 56.0%) identified eyes at elevated risk of calculator disagreement. Conclusion: Calculators’ variability in toric IOL planning is substantial (~60% of eyes) and concentrated in with-the-rule eyes with elevated posterior corneal astigmatism. In this subgroup, consulting multiple calculators is recommended; in against-the-rule eyes, calculator choice rarely alters the recommendation.